292. No association Between Direct-acting Antiviral (DAA) Therapy and Varicella-Zoster Virus (VSV) Reactivation in an Analysis of 37 Prospective Clinical Trials

Background Direct-acting antivirals (DAAs) have substantially increased the rate of sustained virologic response in patients with hepatitis C compared with interferon therapy (IFN), while causing fewer adverse events. However, five recent case series and retrospective studies (Table 1) have reported a possible link between DAA treatment for hepatitis C and reactivation of varicella-zoster virus (VZV). Reported VZV reactivation rates in these studies were 0.23%, 0.72%, 1.50%, 1.74%, and 8.00%.